Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Clinical Investigation · 2011
DOI: 10.4155/cli.10.26 ↗At a glance
Journal article in Clinical Investigation, 2011. Written by Marta Letizia Hribal and 1 co-authors. Cited 1 times so far (Crossref); 64 references.
Topics: Diabetes mellitus
Abstract (original language)
Glucagon-like peptide-1 (GLP-1) analogs-based therapies are a new option for Type 2 diabetes treatment that hold the promise of overcoming the major limitations of traditional treatments, including the increased risk for hypoglycemia and weight gain.GLP-1 is a naturally occurring hormone that potentiates glucose-dependent insulin secretion.The clinical utility of native GLP-1 is, however, limited by its short half-life; these observations led to the generation of GLP-1 analogs, which mimic GLP-1 action in vivo in humans.Here, we review the data from clinical trials that have assessed mechanism of action, efficacy and safety of GLP-1 agonists; these trials have demonstrated the efficacy of GLP-1 analogs in reducing glycosylated hemoglobin and fasting plasma glucose levels.The use of these drugs was associated with weight loss and reductions in blood pressure, with a low risk of hypo glycemia, GLP-1 agonists were generally well tolerated with the most frequent adverse effects being nausea.
Cite
APA
Hribal, M. L., & Sesti, G. (2011). Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. Clinical Investigation. https://doi.org/10.4155/cli.10.26
Vancouver
Hribal ML, Sesti G. Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials. Clinical Investigation. 2011. doi:10.4155/cli.10.26
BibTeX
@article{Hribal2011,
author = {Hribal, Marta Letizia and Sesti, Giorgio},
title = {Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials},
journal = {Clinical Investigation},
year = {2011},
doi = {10.4155/cli.10.26}
}
EUVIMED